INCHEON, South Korea--(BUSINESS WIRE)--Celltrion (KRX:068270), a global biopharmaceutical leader, announced its acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland.

韩国仁川--（商业新闻短讯）--全球生物制药领导者Celltrion（KRX:068270）宣布收购iQone Healthcare Switzerland，这是一家专注于瑞士分销、销售和营销的专业制药公司。

The acquisition, expected to close by Q4, 2024, represents a significant milestone in Celltrion’s European expansion strategy. Upon completion, iQone Healthcare Switzerland will become a wholly owned subsidiary of Celltrion Healthcare Hungary Kft. The deal will also provide Celltrion access to in-licensing opportunities, further strengthening its pipeline of innovative therapies..

此次收购预计将于2024年第四季度完成，是Celltrion欧洲扩张战略的一个重要里程碑。完成后，iQone Healthcare Switzerland将成为Celltrion Healthcare Hungary Kft的全资子公司。

Taehun Ha, Head of Europe and Vice President of Celltrion, Inc., emphasized the acquisition’s importance, stating, “This move represents a strategic shift in our growth strategy. While we have successfully built direct sales networks, we are now leveraging acquisitions to accelerate our European expansion.

Celltrion，Inc.欧洲主管兼副总裁Taehun Ha强调了此次收购的重要性，他表示：“这一举动代表了我们增长战略的战略转变。虽然我们已经成功建立了直销网络，但我们现在正在利用收购来加速我们在欧洲的扩张。

With a distribution network spanning more than 20 regions, we are well-positioned to compete in the increasingly competitive biosimilar market.”.

凭借跨越20多个地区的分销网络，我们在竞争日益激烈的生物仿制药市场中处于有利地位。”

He added, “As a fully integrated company, Celltrion manages every stage of the value chain—from R&D and manufacturing to sales, marketing and distribution. This integration enables us to continue and expand our stable and growing supply of high-quality biosimilars, including in Switzerland, where we aim to further solidify our market presence and portfolio.

他补充道：“作为一家完全整合的公司，Celltrion管理着从研发和制造到销售、营销和分销的价值链的每个阶段。这种整合使我们能够继续并扩大稳定且不断增长的高质量生物仿制药供应，包括在瑞士，我们的目标是进一步巩固我们的市场地位和投资组合。

It also underscores our commitment to leadership through local operational excellence and continuous innovation.”.

它还强调了我们通过本地卓越运营和持续创新来领导的承诺。”

Laurent Massuyeau, founder and Executive Chairman of iQone Healthcare Switzerland, expressed his optimism, stating, “Our successful decade-long partnership with Celltrion has laid very strong foundations for this integration. By combining Celltrion’s portfolio expertise with our established commercial operation, this acquisition will drive growth and enhance access to essential biosimilar and innovative medicines in Switzerland..

瑞士iQone Healthcare创始人兼执行主席劳伦特·马苏约（Laurent Massuyeau）表示乐观，他表示：“我们与Celltrion成功的十年合作伙伴关系为这种整合奠定了非常坚实的基础。通过将Celltrion的投资组合专业知识与我们既定的商业运营相结合，此次收购将推动瑞士的增长，并增进瑞士基本生物仿制药和创新药物的获取。”

True to our values and with the support of the program “iQone for You”, an outstanding set of services directed to healthcare professionals and specially crafted for the Swiss market, we will continue to serve our customers with agility and efficiency and bring new therapeutic opportunities quickly to Switzerland.'.

秉承我们的价值观，在“iQone为您服务”计划的支持下，我们将继续以灵活高效的方式为客户服务，并迅速为瑞士带来新的治疗机会。“iQone为您服务”是一套针对医疗保健专业人员的优质服务，专为瑞士市场精心打造。

About Celltrion

关于Celltrion

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally.

Celltrion是一家位于韩国仁川的领先生物制药公司，专门从事创新疗法的研究、开发、制造、营销和销售，以改善全球人民的生活。该公司的解决方案包括世界一流的单克隆抗体生物仿制药，如Remsima®、Truxima®和Herzuma®，为全球患者提供更广泛的服务。

Celltrion has also received U.S. FDA and EC approval for Vegzelma® and Yuflyma®, FDA approval for Zymfentra®, and EC approval for Remsima® SC, Omlyclo®, SteQeyma®. To learn more, please visit www.celltrion.com/en-us..

。欲了解更多信息，请访问www.celltrion.com/en-us。

About iQone Healthcare Switzerland

关于iQone医疗瑞士

iQone Healthcare, a Swiss-based specialty pharmaceutical company, is dedicated to the commercialization of biosimilars and innovative treatments for rare diseases. Its mission is to ensure that therapeutic advancements are accessible to Swiss patients in a timely manner, providing the care they need when they need it..

瑞士专业制药公司iQone Healthcare致力于生物仿制药的商业化和罕见疾病的创新治疗。其使命是确保瑞士患者能够及时获得治疗进展，并在需要时提供所需的护理。

iQone Healthcare has maintained a decade-long partnership with Celltrion as exclusive distribution partner for Switzerland, successfully marketing Celltrion product range, including Remsima®, Veblocema®, Truxima®, Herzuma®, Vegzelma®, and Yuflyma®.

iQone Healthcare与Celltrion保持了长达十年的合作关系，成为瑞士的独家分销合作伙伴，成功销售Celltrion产品系列，包括Remsima®、Veblocema®、Truxima®、Herzuma®、Vegzelma®和Yuflyma®。

For more information, visit www.iqone-healthcare.com

有关更多信息，请访问www.iqone-healthcare.com

FORWARD-LOOKING STATEMENT

前瞻性声明

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

本新闻稿中的某些信息包含与我们未来的业务和财务业绩以及涉及Celltrion Inc.及其子公司的未来事件或发展相关的报表，这些报表可能构成相关证券法下的前瞻性报表。

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology..

这些声明可以用“准备”，“希望”，“即将到来”，“计划”，“目标”，“即将推出”，“正在准备”，“一旦获得”，“可能”，“目的”，“可能”，“一旦确定”，“将”，“致力于”，“是到期”，“变得可用”，“有潜力”，这些单词的负面或其他类似变体或类似术语。

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.

此外，我们的代表可能会发表口头前瞻性声明。此类声明基于Celltrion Inc.及其子公司管理层的当前预期和某些假设，其中许多超出其控制范围。

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them..

提供前瞻性陈述是为了让潜在投资者有机会了解管理层对未来的信念和意见，以便他们可以将这些信念和意见作为评估投资的一个因素。这些声明并不能保证未来的业绩，不应过分依赖这些声明。

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements..

此类前瞻性报表必然涉及已知和未知的风险和不确定性，这可能导致未来期间的实际业绩和财务业绩与此类前瞻性报表明示或暗示的未来业绩或结果的任何预测存在重大差异。

Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

尽管本演示文稿中包含的前瞻性陈述是基于Celltrion Inc.及其子公司的管理层认为合理的假设，但不能保证前瞻性陈述会被证明是准确的，因为实际结果和未来事件可能与此类陈述中的预期大不相同。

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements..

如果情况或管理层的估计或意见发生变化，Celltrion Inc.及其子公司没有义务更新前瞻性报表，除非适用的证券法另有要求。提醒读者不要过度依赖前瞻性陈述。